BioLineRx Balance Sheet Health
Financial Health criteria checks 5/6
BioLineRx has a total shareholder equity of $14.0M and total debt of $29.4M, which brings its debt-to-equity ratio to 210.6%. Its total assets and total liabilities are $64.6M and $50.6M respectively.
Key information
210.6%
Debt to equity ratio
US$29.45m
Debt
| Interest coverage ratio | n/a |
| Cash | US$40.06m |
| Equity | US$13.98m |
| Total liabilities | US$50.62m |
| Total assets | US$64.60m |
Recent financial health updates
Recent updates
BioLineRx stock slips on $15M securities offering
Sep 19BioLineRx files for FDA approval of motixafortide in stem cell mobilization
Sep 12biolinerx GAAP EPS of -$0.01 beats by $0.08
Aug 16BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer
Jun 29BioLineRx: A Top Candidate For A Takeover Before 2022 Ends
Jun 30biolinerx EPS beats by $0.17
May 26BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma
May 04BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer
Dec 16biolinerx EPS beats by $0.32
Nov 23BioLineRx launches early-stage study with lead asset in COVID-19 related respiratory distress
Nov 18BioLineRx launches mid-stage combo study in first-line pancreatic cancer
Oct 29Financial Position Analysis
Short Term Liabilities: BLRX's short term assets ($49.1M) exceed its short term liabilities ($30.5M).
Long Term Liabilities: BLRX's short term assets ($49.1M) exceed its long term liabilities ($20.1M).
Debt to Equity History and Analysis
Debt Level: BLRX has more cash than its total debt.
Reducing Debt: BLRX's debt to equity ratio has increased from 21.5% to 210.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BLRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BLRX has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 0.1% each year.